key: cord-0776304-n0y1iqxs
authors: François, Bruno; Laterre, Pierre-François; Luyt, Charles-Edouard; Chastre, Jean
title: The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients
date: 2020-06-05
journal: Crit Care
DOI: 10.1186/s13054-020-03013-2
sha: f8e94dad621fbdff943f0d43b668a3c4ce4778d1
doc_id: 776304
cord_uid: n0y1iqxs

nan

The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients Bruno François 1* , Pierre-François Laterre 2 , Charles-Edouard Luyt 3 and Jean Chastre 2 While different phenotypes have been evidenced in ICU COVID-19 pneumonia [1] , most patients meet ARDS Berlin definition associating bilateral radiologic infiltrates with severe hypoxemia. COVID-19 patients frequently require prolonged invasive mechanical ventilation (MV) including prone positioning, heavy sedation, and muscle blockers for several weeks. In addition, there is clear evidence of prolonged immunosuppression including deep lymphopenia [2] . This accounts for a high risk of secondary hospital-acquired infections, primarily ventilator-associated pneumonia (VAP). The diagnosis of ventilator-associated infections remains challenging due to major definition heterogeneity of multiple clinical entities, and no consensus has yet been reached on appropriate diagnostic strategies for VAP. Irrespective of the definition, accurate diagnosis of VAP requires clinical signs of infection, microbiological documentation, and chest X-ray findings, even if the latter may be difficult to interpret due to preexisting parenchymal injury [3] .

The clinical presentation of COVID-19 pneumonia is relatively homogenous and commonly associates high fever, hyperleukocytosis, severe hypoxemia, extensive bilateral radiologic infiltrates, and biological inflammatory syndrome. Since this presentation is shared with VAP, traditional diagnostic criteria for VAP are not valid in the critical COVID-19 population. Similarly, the Clinical Pulmonary Infection Score (CPIS), assessing body temperature, tracheal secretions, radiologic infiltrate, hyperleukocytosis, and PaO 2 /FiO 2 , has little additional value since its components overlap with those of COVID-19 pneumonia in MV patients [4] . In our experience, more than 90% of COVID-19 patients had qualifying CPIS > 6 on day 2 following ICU admission in the absence of any documented VAP or co-infection. Accordingly, the microbiological documentation from deep respiratory secretions currently remains the sole criterion to support VAP diagnosis in COVID-19 patients. Fiberoptic bronchoalveolar lavage is hardly feasible in severely hypoxemic COVID-19 patients due to the inherent risk of worsening hypoxemia. Hence, many ICU perform less invasive endotracheal aspirate (ETA) with quantitative or semiquantitative cultures, even if less reliable for deciding whether to institute antibiotic treatment or not. It is near impossible to distinguish COVID-19-associated ARDS with asymptomatic bacterial colonization from a true VAP based solely on traditional threshold values (i.e., 10 5 CFU/ml for ETA). Interestingly, despite heavy bacterial load, white blood cell count in bronchial secretions appears very low in most COVID-19 patients developing a superinfection. Accurate identification of COVID-19 patients who require treatment with new antibiotics for a clinically relevant bacterial superinfection is difficult, leading to overuse of broad-spectrum antibiotics despite the absence of supporting data in the literature [5] . As a result, most ventilated COVID-19 patients with ARDS are treated with prophylactic antibiotics to prevent from undocumented VAP. Such a strategy is at high risk of selection of multi-drug-resistant bacteria or even fungi in patients expected to remain under invasive MV for a long period. The COVID-19 pandemic and the severity of its clinical presentation cannot justify "emotional" and blind antibiotic therapy on the sole argument that traditional VAP definition is invalid. Specific COVID-19 antimicrobial stewardship and guidelines are required to avoid this detrimental approach, considering that within the first 10 days, most of the pathogens documented in the lung are from the community with minimal resistant profile (unpublished data). While it is reasonable to initiate antibiotics in patients with suspected VAP and hemodynamic instability or severe hypoxemia following European guidelines [6] regardless of clinical certainty, a more conservative approach may be beneficial for stable patients (Fig. 1) . It remains to be seen whether routine assessment tools such as daily variations of CPIS score, serial viral load aspirates, new molecular techniques, or lung ultrasonography will help improving decisions regarding antibiotic treatment in such a clinically complex population. Diagnostic algorithms using a PCT-guided strategy for stopping early empiric antimicrobial treatment [7] or pathogen quantification trends could be alternatively tested for VAP diagnosis. Overall, studies in this field are urgently needed. 

COVID-19 pneumonia: ARDS or not?

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Does this patient have VAP?

Clinical pulmonary infection Fig. 1 Empiric antibiotic treatment decision tree for HAP/VAP in COVID-19 patients score for ventilator-associated pneumonia: accuracy and inter-observer variability

Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing

International ERS/ESICM/ ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the

Procalcitonin to guide antibiotic therapy in the ICU

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Authors' contributions BF, PFL, CEL, and JC wrote the manuscript. They all reviewed and approved the final version.